Retinal Vein Occlusion (RVO)

Retinal vein occlusion is a blockage of a retinal vein. It is a common cause of sudden painless reduction in vision in older people. The blockage of a vein causes blood and other fluids to leak into the retina which causes damage that reduces vision. RVO is more common in later life.

Types of retinal vein occlusion
1. Branch Retinal Vein Occlusions (BRVO) are due to obstruction of one of the four retinal veins.

2. Central Retinal Vein Occlusion (CRVO) is due to obstruction of the main vein formed from the four branches which drain blood from the retina. This type generally causes more severe vision loss.

RVO is caused by a blocked vein, often due to a clot which completely obstructs blood flow. Conditions that make RVO more likely include: high blood pressure; high cholesterol; glaucoma; diabetes; smoking; and certain rare blood disorders. Treatment of the risk factors dramatically reduces the risk of a further vein occlusion.

Diagnostic tests
- Optical coherence tomography (OCT) scans measure retinal swelling (macular oedema).
- Fluorescein dye angiography. A dye injected into a vein in the arm travels to the eye, highlighting the blood vessels in the retina so they can be photographed.

Treatment
1. Fluid in the retina (macular oedeama)
Anti-VEGF injections or steroids implants injected into the eye are used to treat RVO. The injections have to be repeated over a period of time to work effectively.

Injection treatment aims to stabilise or improve vision. About 45-55% of patients treated with anti-VEGF injections experience a significant gain in vision. Steroid implants achieve a significant gain in vision in up to 30% of patients. 20-30% of patients experience no improvement in vision treatment. Laser treatment may be used to treat branch retinal vein occlusions.

Observation or monitoring is an option for people who prefer not to have treatment for macular oedema. Branch retinal vein occlusions have a better chance of natural resolution than central retinal vein occlusions. However treatment has been shown to achieve the best results.

2. Abnormal new blood vessel growth (neovascularisation) About 20% of patients with RVO develop abnormal blood vessels that can bleed or increase pressure in the eye, leading to further loss of vision.

This can normally be prevented by laser treatment to stabilise and preserve the condition of the eye, but not improve vision.

**Follow-up**
Patients with CRVO are reviewed every four to eight weeks for about six months and then less frequently. Most patients are discharged after one to two years.

Patients with BRVO are normally reviewed at four to six-monthly intervals for one to two years.